ImmunityBio, Inc. IBRX Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s total current assets?
- ImmunityBio, Inc. (IBRX) reported total current assets of $452.95M in Q1 2026.
- How has ImmunityBio, Inc.'s total current assets changed year-over-year?
- ImmunityBio, Inc.'s total current assets increased by 314.9% year-over-year, from $109.16M to $452.95M.
- What is the long-term trend for ImmunityBio, Inc.'s total current assets?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s total current assets has grown at a 23.0% compound annual growth rate (CAGR), from $111.71M to $314.88M.
- What does total current assets mean?
- The sum of all assets that the company expects to turn into cash within one year.
- How do you interpret total current assets?
- Higher levels indicate stronger short-term liquidity and operational flexibility to support ongoing R&D and clinical programs.
- How does total current assets compare across companies?
- Crucial for biotech companies to assess their ability to sustain operations without external financing.